

CURRICULUM VITAE

NAME: **Gary A. Thompson, PhD, FAAPS, FCP**
PLACE OF BIRTH: Ft. Roberts, California

WORK ADDRESS: **GA Thompson Consulting, LLC**
6124 Holly Hill Lane
West Chester, Ohio 45069
USA

513-235-1498 (voice)
248-461-0952 (eFax)
gat.consulting@gmail.com (email)

EDUCATION:

1976 **B.S. Pharm.**, University of Cincinnati,
Cincinnati, Ohio, USA

1983 **Ph.D.**, University of Cincinnati,
Cincinnati, Ohio, USA; Pharmacokinetics
and Biopharmaceutics

LICENSURE:

Pharmacist - Ohio (#03-3-11887)

EXPERIENCE:

January, 2014 to present **Adjunct Professor of Pharmaceutics,**
Division of Pharmaceutical Sciences,
James L. Winkle College of Pharmacy,
University of Cincinnati, Cincinnati, Ohio

January 2014 to present **Advisory Board Member,** sY-co
Business Services, Faoug, Switzerland

January, 2009 to present **Principal;** GA Thompson Consulting,
LLC, Cincinnati, Ohio.

Gary A. Thompson, PhD, FAAPS, FCP

December, 2001 to December, 2008

Research Fellow; Clinical Pharmacology and Pharmacokinetics Department, Regulatory and Clinical Development, Procter and Gamble Pharmaceuticals; Mason, Ohio.

December, 1995 –December, 2001

Principal Scientist; Clinical Pharmacology and Pharmacokinetics Department, Regulatory and Clinical Development, Procter and Gamble Pharmaceuticals; Cincinnati, Ohio.

March, 1994 – July, 1999

Adjunct Associate Professor of Pharmacokinetics, Division of Pharmaceutics and Drug Delivery Systems, College of Pharmacy, University of Cincinnati, Cincinnati, Ohio (reappointment - July 1, 1996).

March, 1994 - March, 1995

Advisor, Board of Directors, Drug Emporium, Inc. Columbus, Ohio.

February, 1992 - December, 1995

Senior Scientist; Clinical Pharmacology and Pharmacokinetics Department, Regulatory and Clinical Development, Procter and Gamble Company; Cincinnati, Ohio.

November, 1991 – July, 2006

Volunteer Assistant Professor of Clinical Anesthesia; Department of Anesthesia, University of Cincinnati College of Medicine, Cincinnati, Ohio (reappointment - September 1, 1996).

June, 1991 - February, 1992

Senior Research Pharmacokineticist III; Marion Merrell Dow Inc., Cincinnati, Ohio.

April, 1985 - June, 1991

Senior Research Pharmacokineticist II; Merrell Dow Research Institute, Cincinnati, Ohio.

Dec., 1983 - April, 1985

Senior Research Biochemist; Merrell Dow Research Institute, Cincinnati, Ohio.

* corresponding author

Gary A. Thompson, PhD, FAAPS, FCP

Sept., 1981 - Sept., 1983

**Adjunct Instructor of
Biopharmaceutics;** University of
Cincinnati, College of Pharmacy,
Cincinnati, Ohio.

Sept., 1976 - June, 1981

Graduate Teaching Assistant;
University of Cincinnati, College of
Pharmacy, Cincinnati, Ohio;

PROFESSIONAL MEMBERSHIPS:

American Association for the
Advancement of Science

American Association for Pharmaceutical
Scientists

American College of Clinical
Pharmacology

American Pharmaceutical Association

American Pharmaceutical Association
Academy of Pharmaceutical Research and
Science

American Society for Clinical
Pharmacology and Therapeutics

Drug Information Association

Ohio Pharmacists Association

The International Society for the Study of
Xenobiotics

Indiana – Ohio Discussion Group
associated with American Association for
Pharmaceutical Scientists (formerly
Indianapolis – Cincinnati Discussion
Group)

* corresponding author

PROFESSIONAL COMMITTEES:

| | |
|-------------------------|--|
| <i>1988 - 1989</i> | Chair-Elect; Indianapolis-Cincinnati Discussion Group, Association of Pharmaceutical Scientists |
| <i>1989 - 1990</i> | Chair; Indianapolis-Cincinnati Discussion Group, Association of Pharmaceutical Scientists |
| <i>1990 - 1992</i> | Past-Chair; Indianapolis-Cincinnati Discussion Group, Association of Pharmaceutical Scientists |
| <i>1992 - 2003</i> | Advisor; Indianapolis-Cincinnati Discussion Group, Association of Pharmaceutical Scientists |
| <i>1993</i> | Chair; Annual Booth; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |
| <i>1995, 1998</i> | Chair; Midwest Users Forum for Population Approaches in Data Analysis |
| <i>1998 - 1999</i> | Member; Program Committee, International Industrial Pharmacy Conference, The University of Texas at Austin |
| <i>1998</i> | Member; Program Committee for <i>Biopharmaceutics and Pharmacokinetics in Drug Development: Perspectives for the Millennium</i> - A Symposium honoring Professor Emeritus Wolfgang Ritschel |
| <i>1998, 1999, 2004</i> | Member; PPDM Open Forum Committee, American Association of Pharmaceutical Scientists |
| <i>1998 - 2008</i> | Member; Clinical Pharmacology Technical Working Group, Pharmaceutical Research and Manufacturers of America (PhRMA) |

* corresponding author

| | |
|------------------------|--|
| 2000, 2001 | Chair; PPDM Abstract Screening; American Association of Pharmaceutical Scientists |
| 2000 | Member; Program Committee, International Conference on Drug Development, The University of Texas at Austin |
| 2000, 2001, 2005, 2006 | Reviewer; AAPS Graduate Symposium in Pharmacokinetics, Pharmacodynamics and Clinical Sciences |
| 2001 – 2003 | Secretary/Treasurer; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |
| 2002 | Member; Portal Redesign Committee, American Association of Pharmaceutical Scientists |
| 2003 – 2006 | Member; Education Committee, American Society of Clinical Pharmacology and Therapeutics |
| 2003 – 2004 | Vice Chair; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |
| 2003 – 2005 | Member; Section/Focus Group Committee, American Association of Pharmaceutical Scientists |
| 2003 – 2004 | Member; Portal Review Team, American Association of Pharmaceutical Scientists |
| 2004 – 2005 | Chair-Elect; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |

Gary A. Thompson, PhD, FAAPS, FCP

| | |
|-------------|--|
| 2004 – 2005 | Member; Annual Meeting Program Committee, American Association of Pharmaceutical Scientists |
| 2005 – 2012 | Member; Editorial Board, Biopharmaceutics and Drug Disposition, John Wiley and Sons, LTD |
| 2005 – 2006 | Chair; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |
| 2005 – 2006 | Member; Nomination Committee, American Association of Pharmaceutical Scientists |
| 2006 – 2007 | Past-Chair; Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section, American Association of Pharmaceutical Scientists |
| 2006 – 2007 | Member; Program Coordination Committee, American Association of Pharmaceutical Scientists |
| 2006 - 2008 | Secretary; Clinical Pharmacology Technical Working Group, Pharmaceutical Research and Manufacturers of America (PhRMA) |
| 2006 – 2007 | Member; AAPS Emerging Regulatory Guidances Task Force, American Association of Pharmaceutical Scientists |
| 2006 – 2007 | Member; AAPS Finance Committee Task Force, American Association of Pharmaceutical Scientists |
| 2007 – 2008 | Member; Cough/Cold Pediatric Pharmacokinetic Task Force, Consumer Healthcare Products Association |

* corresponding author

| | |
|-------------|---|
| 2008 – 2011 | Member at Large; AAPS Executive Committee, American Association of Pharmaceutical Scientists |
| 2008 – 2009 | Member at Large Representative; AAPS Membership Strategic Oversight Committee, American Association of Pharmaceutical Scientists |
| 2008 – 2010 | Member at Large Representative; AAPS Discovery Development Interface Committee, American Association of Pharmaceutical Scientists |
| 2008 – 2009 | Member at Large Representative; AAPS Clinical Pharmacology and Translational Research Section, American Association of Pharmaceutical Scientists |
| 2008 – 2010 | Member at Large Representative; AAPS Drug Design and Discovery Section, American Association of Pharmaceutical Scientists |
| 2009 - 2010 | Member; AAPS Quantitative Model Based Drug Development Task Force, Structure and Sustainability subteam, American Association of Pharmaceutical Scientists |
| 2009 – 2010 | Member at Large Representative; AAPS Regulatory Sciences Committee, American Association of Pharmaceutical Scientists |
| 2009 – 2010 | Member at Large Representative; AAPS National Biotechnology Conference Committee, American Association of Pharmaceutical Scientists |
| 2009 – 2010 | Member at Large Representative; AAPS National Biotechnology Conference Abstract Screening Committee, American Association of Pharmaceutical Scientists |

| | |
|-------------|--|
| 2010 – 2011 | Member at Large Representative; AAPS Annual Meeting Program Committee, American Association of Pharmaceutical Scientists |
| 2010 – 2011 | Member at Large Representative; AAPS Annual Meeting Abstract Screening Committee, American Association of Pharmaceutical Scientists |
| 2010 – 2011 | Member at Large Representative; AAPS Representative on Model Based Drug Development, American Association of Pharmaceutical Scientists |
| 2010 – 2011 | Member at Large Representative; AAPS Clinical Pharmacology and Translation Research Section, American Association of Pharmaceutical Scientists |
| 2010 – 2011 | Member at Large Representative; AAPS Manufacturing and Engineering Section, American Association of Pharmaceutical Scientists |
| 2010 – 2011 | Member at Large Representative; AAPS Elections Task Force, American Association of Pharmaceutical Scientists |

ACADEMIC COMMITTEES:

1991- 2006

Anesthesia Research Committee,
Department of Anesthesia, University of
Cincinnati Medical School, Cincinnati,
OH.

1997 - 2000

**Sharon Haines, Ph.D. Dissertation
Committee;** Dissertation Title: Relative
Bioavailability of Estradiol and
Norethindrone after a Single Application
of an Estradiol Progestin Matrix
Transdermal System, University of
Cincinnati, College of Nursing, Cincinnati,
OH

2013 to present

Zaid Al-Shammaa, MS Thesis Committee;
University of Cincinnati, College of
Pharmacy, Cincinnati, OH

HONORS:

| | |
|------|--|
| 1977 | Rho Chi Pharmaceutical Honor Society , University of Cincinnati, Cincinnati, OH. |
| 1979 | Clinical Pharmacology Fellowship , Institute for Clinical Pharmacology, Bobenheim am Berg, West Germany |
| 1987 | Who's Who in the Midwest , 21st Edition |
| 1988 | Who's Who of Emerging Leaders in America , 2nd Edition |
| 1990 | Who's Who of Emerging Leaders in America , 3rd Edition |
| 2000 | Who's Who in Science and Engineering , 5th Edition |
| 2005 | Fellow , American Association of Pharmaceutical Scientists, Arlington, VA |
| 2006 | Who's Who in Science and Engineering , 9th Edition |
| 2007 | Who's Who in Science and Engineering , 10th Edition |
| 2008 | Fellow , American College of Clinical Pharmacology, New Hartford, NY |
| 2010 | President-Elect Candidate , American Association of Pharmaceutical Scientists, Arlington, VA |

REVIEWER:

AAPS PharmSci

British Journal of Clinical Pharmacology

Biopharmaceutics and Drug Disposition

Clinical Pharmacology and Therapeutics

Clinical Pharmacology in Drug
Development

Drug Intelligence and Clinical Pharmacy

Drug Metabolism Reviews

International Journal of Clinical
Pharmacology, Therapy and Toxicology

Journal of Clinical Pharmacology

Journal of Pharmaceutical Sciences

Journal of Pharmacokinetics and
Pharmacodynamics

Life Sciences

Pharmaceutical Research

Toxicology and Applied Pharmacology

American Association of Pharmaceutical
Scientist: Pharmacokinetics,
Pharmacodynamics and Drug
Metabolism Abstracts - 1990, 1993,
1994, 1996, 1999, 2000, 2002, 2003,
2004, 2005, 2006, 2007, 2008, 2009,
2011, 2012, 2013, 2014

MAJOR RESEARCH INTERESTS:

Pharmacokinetics
Pharmacodynamics
Mathematical Modeling
Drug Development
Drug-Drug Interactions
Sparse Data Analysis
Software Development
Bioavailability

BIBLIOGRAPHY:

Book Contributions

1. Ritschel WA*, **Thompson GA**: The one-point method for prediction of dosage regimen to maintain a desired minimum steady state concentration in patients with changed volume of distribution and/or changed renal and extrarenal elimination. In PHARMACOKINETICS, Gladtko and Heimann (eds.), Stuttgart, Gustav Fischer Verlag, 1980, pp. 141-150.
2. Denson DD*, Turner PA, Bridenbaugh PO, **Thompson GA**: CSF pharmacokinetics following intravenous and epidural lidocaine. In NEW ASPECTS IN REGIONAL ANESTHESIA, Wust and Stanton-Hicks (eds.), Heidelberg, Verlag fur Medizin Dr. Ewald Fischer GmbH, 1988, pp. 54-63.
3. Skare J*, Murphy VA, Bookstaff RC, **Thompson GA**, Heise MA, Horowitz ZD, Parkinson A, St. Peter JV: Safety Assessment of OTC drugs: Doxylamine Succinate. In TOXICOLOGY IN TRANSITION - PROCEEDINGS OF THE 1994 EUROTOX CONGRESS, Degen, Seiler and Bentley (eds.), Berlin, Springer-Verlag, 1995, pp. 326-340.
4. **Thompson GA***, Burgio DE: The Role of Metabolite Pharmacokinetics and Pharmacodynamics in Drug Development. In PHARMACOKINETICS IN DRUG DEVELOPMENT VOLUME 1: CLINICAL STUDY DESIGN AND ANALYSIS, Bonate and Howard (eds.), Arlington, VA, AAPS Press, 2004, pp. 321-346.

* corresponding author

Book Reviews:

1. **Thompson GA**, Boxenbaum H: DRUG DYNAMICS FOR ANALYTICAL, CLINICAL, AND BIOLOGICAL CHEMISTS, BJ Gudzinowicz, BT Younkin, MJ Gudzinowicz, Marcel Dekker, Inc., NY. J Pharm Sci 74: 1141-1142, 1985.

Journal Articles:

1. Ritschel WA*, Hammer GV, **Thompson GA**: Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol 16: 395-401, 1978.
2. Ritschel WA*, **Thompson GA**: The one-point method in predicting dosage regimens in cases of hepatic and/or renal failure in presence or absence of change in volume of distribution. J Clin Pharmacol 19: 350-356, 1979.
3. Ritschel WA*, **Thompson GA**, Luckner PW, Wetzelsberger K: Biopharmaceutical evaluation of etofylline clofibrate and its drug formulation. Arzneim Forsch/Drug Res 30: 2020-2023, 1980.
4. Berry PL*, Kearns GL, Brown RD, Ritschel WA, **Thompson GA**, McEnery PT: Gentamicin disposition in children with chronic renal failure. Ped Pharmacol 2: 257-273, 1982.
5. Ritschel WA*, **Thompson GA**: Monitoring of drug concentrations in saliva: A noninvasive pharmacokinetic procedure. Meth and Find Exptl Clin Pharmacol 5: 511-525, 1983.
6. Denson D*, Coyle D, **Thompson G**, Myers J: Alpha1-acid glycoprotein and albumin in human serum binding of bupivacaine. Clin Pharm Ther 35: 409-415, 1984.
7. Denson DD*, Turner PA, Bridenbaugh PO, **Thompson GA**: Pharmacokinetics and neural blockade following subarachnoid lidocaine in the rhesus monkey. III. Effects of Phenylephrine. Anesth Analg 63: 129-133, 1984.
8. Denson DD*, Coyle DE, **Thompson GA**, Santos D, Turner PA, Myers JA, Knapp R: Bupivacaine protein binding in the term parturient: Effects of lactic acidosis. Clin Pharm Ther 35: 702-709, 1984.
9. Coyle DE*, Denson DD, **Thompson GA**, Myers JA, Arthur GR, Bridenbaugh PO: The influence of lactic acid on the serum protein binding of bupivacaine: Species differences. Anesthesiology 61: 127-133, 1984.

* corresponding author

10. **Thompson GA***, Myers JA, Turner PA, Denson DD, Coyle DE, Ritschel WA: Influence of cimetidine on bupivacaine disposition in rat and monkey. *Drug Met Disp* 12: 625-630, 1984.
11. Denson DD*, Myers JA, **Thompson GA**, Coyle DE: The influence of diazepam on the serum protein binding of bupivacaine at normal and acidic pH. *Anesth Analg* 63: 980-984, 1984.
12. Denson DD*, **Thompson GA**, Raj PP, Finnsson RA, Myers JA, Thurman BH: Continuous perineural infusion of bupivacaine for prolonged analgesia: A rapid two point method for estimating individual pharmacokinetic parameters. *Int J Clin Pharmacol Ther Toxicol* 22: 552-556, 1984.
13. Denson DD*, Knapp RM, Turner P, **Thompson GA**: Serum bupivacaine concentration in term parturients following continuous epidural analgesia for labor and delivery. *Ther Drug Monit* 6: 393-398, 1984.
14. Scharf MB*, Denson DD, **Thompson GA**, Goff PJ: Carryover hypnotic effectiveness of diazepam. *Curr Ther Res* 37: 309-317, 1985.
15. **Thompson GA**, Turner PA, Bridenbaugh PO, Stuebing RC, Denson DD*: The influence of diazepam on the pharmacokinetics of intravenous and epidural bupivacaine in the rhesus monkey. *Anesth Analg* 65: 151-155, 1986.
16. Denson DD*, **Thompson GA**, Coyle DE: Use of a limited physiologic model to explain target organ toxicity of bupivacaine as a function of route of administration. *Biopharm Drug Disp* 7: 121-135, 1986.
17. **Thompson GA**, Ritschel WA*: The repeated one-point method for predicting dose sizes with irregular dosing intervals. *Int J Clin Pharmacol Ther Toxicol* 24: 337-343, 1986.
18. **Thompson GA***, Myers JA, Turner PA, Coyle DE, Ritschel WA, Denson DD: Influence of age on intrinsic clearance of bupivacaine and its reduction by cimetidine in elderly male rats. *Drug Met Disp* 15: 136-137, 1987.
19. Okerholm RA*, Chan KY, Lang JF, **Thompson GA**, Ruberg SJ: Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. *Am J Cardiol* 60: 21C-26C, 1987.
20. Shumaker RC*, Boxenbaum H, **Thompson GA**: ABSPLOTS: A Lotus 123 spreadsheet for calculating and plotting drug absorption rates. *Pharm Res* 5: 247-248, 1988.
21. Hook RH*, Boxenbaum H, **Thompson GA**, Okerholm RA: Human serum and plasma protein binding of enoximone and its sulfoxide metabolite. *J Pharm Sci* 77: 1012-1017, 1988.

* corresponding author

22. **Thompson GA***, Shumaker RC: MLTIDOSE: A multiple-dose simulation program for linear systems characterized by exponential functions. *Drug Metabolism Rev* 21: 463-469, 1989-90.
23. **Thompson GA**, Smithers J, Boxenbaum H*: Biphasic mortality response of chipmunks in the wild to single doses of ionizing radiation: Toxicity and longevity hormesis. *Drug Metabolism Rev* 22: 269-289, 1990.
24. Rybak MJ*, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA**, Kenny MT, Yuh L: Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. *Antimicrobiol Agents Chemother* 35: 696-700, 1991.
25. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, **Thompson GA***: Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. *J Pharm Sci* 80: 605-607, 1991.
26. Smithers JA, Kulmala HK, **Thompson GA***, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA: Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12 and 30 milligrams per kilogram of body weight to healthy male volunteers. *Antimicrobiol Agents Chemother* 36: 115-120, 1992.
27. Pedraz JL, Calvo B, Smithers JA, **Thompson GA***: Pharmacokinetic-Pharmacodynamic Modeling: Time-dependent protein binding - an alternative interpretation of clockwise and counterclockwise hysteresis. *J Pharm Sci* 81: 232-236, 1992.
28. **Thompson GA***, Smithers JA, Kenny MT, Dulworth JK, Kulmala HK, Yuh L, Lewis EW, Antony KK: Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers. *Biopharm Drug Disp* 13: 213-220, 1992.
29. **Thompson GA***: Dosage regimen design: A pharmacokinetic approach. *J Clin Pharmacol* 32: 210-214, 1992.
30. Smithers JA, **Thompson GA***, Kenny MT, Dulworth JK, Kulmala HK, Lewis EW, Ruberg SJ, Shapiro BE, Keane WF, Halstenson CE: Applicability of teicoplanin dosage adjustment nomograms for renally impaired patients over the range of 3 to 30 mg/kg. *Biopharm Drug Disp* 13: 571-581, 1992.
31. Katz JA*, Sehlhorst CS, **Thompson GA**, Denson DD, Coyle D, Bridenbaugh PO: Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. *Biopharm Drug Disp* 14: 578-588, 1993.

* corresponding author

32. **Thompson GA***, St. Peter JV, Heise MA, Horowitz ZD, Salyers GC, Charles TT, Brezovic C, Russell DA, Skare JA, Powell JH: Assessment of Doxylamine Influence on Mixed Function Oxidase Activity Upon Multiple Dose Oral Administration. *J Pharm Sci* 85: 1242-1247, 1996.
33. Davis DAP, Kraus AL, **Thompson GA**, Olerich M, Odio MR*: Percutaneous absorption of salicylic acid after repeated (14-day) in-vivo administration to human normal, acneogenic or aged skin. *J Pharm Sci*: 86:896-899, 1997.
34. Hamman MA, **Thompson GA**, Hall SD*: Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochem Pharm* 54:33-41, 1997.
35. Corey AE, Agnew JR, Valentine SN, Nesbitt JD, Wagner DL, Powell JH, **Thompson GA***: Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. *J Clin Pharmacol* 39: 1272-1276, 1999.
36. Mitchell DY, Eusebio RA, Sacco-Gibson NA, Pallone KA, Kelly SC, Nesbitt JD, Brezovic CP, **Thompson GA***, Powell JH: Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. *J Clin Pharmacol* 40: 258-265, 2000.
37. Mitchell DY, St. Peter JV, Eusebio RA, Pallone KA, Kelly SC, Russell DA, Nesbitt JD, **Thompson GA***, Powell JH: The effect of renal function on risedronate pharmacokinetics after a single oral dose. *Br J Clin Pharmacol* 49: 215-222, 2000.
38. Corey AE, Agnew JR, Valentine SN, Nesbitt JD, Wagner DL, Powell, JH, **Thompson GA***: Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states. *Br J Clin Pharmacol* 49: 279-282, 2000.
39. Mitchell DY, Barr WH, Eusebio RA, Pallone Stevens KA, Duke FP, Russell DA, Nesbitt JD, Powell JH, **Thompson GA***: Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. *Pharmaceut Res* 18: 166-170, 2001.
40. Phillips L, Grasela TH, Agnew JR, Ludwig EA, **Thompson GA***: A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. *Clin Pharmacol Ther* 70: 370-383, 2001.
41. Corey AE, Agnew JR, Valentine SN, Parekh, Powell JH, **Thompson GA***: Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. *Br J Clin Pharmacol* 54: 449-452, 2002.

* corresponding author

42. Hull D^{*}, Wright C, Cronin J, Dobroszi D, Hoke S, Noronha A, Pavesi L, Sakhardande A, **Thompson G**, Weeks A, Wilson A, Morice A: Optimised delivery of an antitussive improves effectiveness. *Eur Respir Rev*: 12: 270-274, 2002.
43. El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, **Thompson GA^{*}**: Influence of azimilide on CYP2C19 mediated metabolism. *J Clin Pharmacol* 44: 373-378, 2004.
44. Corey AE, Agnew JR, King EC, Parekh N, Powell JH, **Thompson GA^{*}**: Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration. *J Pharm Sci* 93: 1279-1286, 2004.
45. **Thompson GA^{*}**, Toothaker RD. Urinary excretion: does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear? *Pharm Res* 21: 781-784, 2004.
46. El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, **Thompson GA^{*}**: Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. *Br J Clin Pharmacol* 58: 641-647, 2004.
47. Toothaker RD, Corey AE, Valentine SN, Agnew JR, Parekh N, Moehrke W, **Thompson GA^{*}**, Powell JH: Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. *J Clin Pharm* 45: 773-780, 2005.
48. Riley P^{*}, Figary PC, Entwisle JR, Roe AL, **Thompson GA**, R Ohashi R, Ohashi N, Moorehead TJ. The metabolic profile of azimilide in man: in vivo and in vitro evaluations. *J Pharm Sci* 94: 2084-2095, 2005.
49. Eichhold TH, McCauley-Myers DL, Khambe DA, **Thompson GA**, Hoke II SH^{*}: Simultaneous determination of dextromethorphan, dextropropoxyphene, and guaifenesin in human plasma using semi-automated liquid/liquid extraction and gradient liquid chromatography tandem mass spectrometry. *J Pharm Biomed Anal* 43: 586-600, 2007.
50. Balan G^{*}, Thompson GA, Gibb R, Li L, Hull D, Seeck M: Doxylamine Pharmacokinetics Following Single Dose Oral Administration in Children Ages 2 - 17 Years. *J Clin Pharmacol* 53: 1177-1185, 2013.
51. Shumaker R^{*}, Aluri J, Fan J, Martinez G, Thompson GA, Ren M: Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults. *Clinical Drug Investigation* (accepted for publication).
52. Shumaker R^{*}, Aluri J, Fan J, Martinez G, Thompson GA, Ren M: Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants. *Clinical Pharmacology in Drug Development* (accepted for publication).

* corresponding author

Letters to the Editor:

1. Denson DD, Myers JA, **Thompson GA**, Coyle DE: Diazepam and free plasma bupivacaine concentrations - In response. *Anesth Analg* 65: 314, 1986.

Abstracts:

1. Denson DD, Myers JA, **Thompson GA**, Raj PP: Enzyme kinetics of bupivacaine, etidocaine, lidocaine and 2,6-pipecoloxylidide (PPX) using rat hepatocytes. *Anesthesiology* 57: A234, 1982.
2. Denson DD, **Thompson GA**, Myers JA: Cimetidine inhibits bupivacaine metabolism. *Reg Anes* 8: 42, 1983.
3. Coyle DE, Denson DD, **Thompson GA**, Myers JA, Arthur GR: Species differences of bupivacaine protein binding. *Anesthesiology* 59: A207, 1983.
4. **Thompson GA**, Ritschel WA: The repeated one-point method for predicting dose sizes with irregular dosing intervals. APHA Academy of Pharmaceutical Sciences Meeting. New Orleans, 1983.
5. Denson DD, Turner PA, Bridenbaugh PO, **Thompson GA**: CSF pharmacokinetics following intravenous and epidural lidocaine. *Anesthesiology* 63: A211, 1985.
6. Hurst GH, Smithers JA, Stuhler JD, **Thompson GA**, Olberding EL: Interspecies comparisons of vigabatrin (gamma-vinyl GABA) absorption and disposition. APHA Academy of Pharmaceutical Sciences Meeting. Minneapolis, 1985.
7. **Thompson GA**, Boxenbaum H, Keeley FJ, Theile JD, Okerholm RA: Absorption and disposition of piroximone (MDL 19205) in congestive heart failure. *Pharm Res* 3: 106S, 1986.
8. Hook RH, Boxenbaum H, **Thompson GA**, Okerholm RA: Human serum and plasma protein binding of enoximone and its sulfoxide metabolite. *Pharm Res* 5: S215, 1988.
9. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA**, Kenny MT: Teicoplanin (T) pharmacokinetics (PK) in intravenous drug abusers (IVDAs) being treated for bacterial endocarditis (BE). Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, 1989.
10. St. Peter WL, Awni WM, Matzke GR, **Thompson GA**: Multiple-dose teicoplanin pharmacokinetics (pk) in infected hemodialysis (hd) patients utilizing a new fluorescence polarization immunoassay (FPIA). *Pharmacotherapy* 10: 239, 1990.

11. Pedraz JL, Calvo B, Smithers JA, **Thompson GA**: Pharmacokinetic-Pharmacodynamic Modeling: Time-dependent protein binding, an alternative interpretation of clockwise and counterclockwise hysteresis. *Pharm Res* 7: S-219, 1990.
12. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, **Thompson GA**: Pharmacokinetics and bioavailability of teicoplanin following single dose intravenous and intramuscular administration of 6 mg/kg to normal, healthy, male volunteers. *Pharm Res* 7: S-206, 1990.
13. Khor SP, Mayersohn M, **Thompson GA**: Teicoplanin (TCP) plasma protein binding by ultrafiltration (UF) and equilibrium dialysis (ED). *Pharm Res* 7: S-256, 1990.
14. Smithers JA, **Thompson GA**, Kenny MT, Dulworth JK, Kulmala HK, Lewis EW, Ruberg SJ, Shapiro BE, Keane WF, Halstenson CE: Applicability of teicoplanin dosage adjustment nomograms for renally impaired patients over the range of 3 to 30 mg/kg. *Pharm Res* 8: S-313, 1991.
15. Smithers JA, Kulmala HK, **Thompson GA**, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA: Pharmacokinetics of teicoplanin upon multiple dose intravenous administration of 3, 12 and 30 mg/kg to normal healthy male volunteers. *Pharm Res* 8: S-313, 1991.
16. Katz JA, Sehlhorst CS, **Thompson GA**, Denson DD, Coyle DR, Bridenbaugh PO: Pharmacokinetics of ropivacaine following intravenous and epidural administration in the rhesus monkey. *Pharm Res* 9: S-261, 1992.
17. **Thompson GA**, St. Peter JV, Heise MA, Horowitz ZD, Salyers GC, Charles TT, Brezovic C, Russell DA, Skare JA, Powell JH: Influence Of Doxylamine Succinate On Mixed Function Oxidase Activity Upon Multiple Dose, Oral Administration. *Pharm Res* 11: S-335, 1994.
18. Mitchell DY, van den Ouweland FA, Heise MA, Salyers GC, Russell DA, Brezovic CP, **Thompson GA**: Effect of food on risedronate pharmacokinetics in healthy volunteers. *Pharm Res* 11: S-370, 1994.
19. **Thompson GA**, Barker SH, Brezovic CP, Williams MB, Powell JH, Kindberg CG: Ibuprofen pharmacokinetics are stereoselectively altered by food. *Pharm Res* 13: S-413, 1996.
20. Buch A, Barker S, Duke F, Kindberg C, Powell J, **Thompson GA**: Lack of pharmacokinetic interaction between ibuprofen (I) and caffeine (C) administered as a combination tablet. *Pharm Res* 13: S-433, 1996.

21. Hamman MA, **Thompson GA**, Hall SD: Regioselective and stereoselective biotransformation of ibuprofen by the human cytochrome P450 2C subfamily. ISSX Proceedings 10: 353, 1996.
22. Mitchell D, Eusebio R, Pallone K, Clay M, Russell D, **Thompson G**: Bisphosphonate pharmacokinetics: Use of simultaneous modeling of urine and serum data to determine parameters. Clin Pharm Ther 61:155, 1997.
23. **Thompson GA**, Powell JH, Mallikaarjun S: Bisphosphonate renal clearance: Assessment of linearity. Pharm Res 14:S-510, 1997.
24. Mitchell DY, Eusebio RA, Pallone KA, Kelly SC, Nesbitt JD, Brezovic CP, **Thompson GA**, Powell JH: Single dose linearity of risedronate following oral administration of 2.5, 5 or 30 mg to healthy volunteers. Pharm Res 14:S-609, 1997.
25. Mitchell DY, Barr WH, Eusebio RA, Pallone KA, Duke FP, Russell DA, Nesbitt JD, Powell JH, **Thompson GA**: Determination of intravenous pharmacokinetics, absolute and relative bioavailability, and intra- and inter-subject variability of risedronate using a four period replicated study design. Pharm Res 14:S-610, 1997.
26. Corey AE, Agnew JR, Comer PF, Dilzer S, Lasseter K, Parekh N, Powell JH, Valentine S, **Thompson GA**: Effect of hepatic impairment on azimilide pharmacokinetics following single dose oral administration. PharmSci 1: S-464, 1998. Available from: <http://www.aapspharmsci.org/>.
27. Mitchell DY, **Thompson GA**, Eusebio RA, Pallone KA, Clay ME, Russell DA, Nesbitt JD, Powell JH: Risedronate pharmacokinetics upon multiple dose oral administration to postmenopausal women for six months. Clin Pharm Ther 65: 189, 1999.
28. Corey AE, Agnew JR, Valentine SN, Parekh, Powell JH, **Thompson GA**: Effect of severe renal impairment on azimilide pharmacokinetics following single dose oral administration. PharmSci 1 (4): S-23, 1999. Available from: <http://www.aapspharmsci.org/>.
29. Phillips L, **Thompson GA**, Grasella TH, Agnew JR: Phase III population pharmacokinetics and pharmacodynamics of azimilide. PharmSci 1 (4): S-83, 1999. Available from: <http://www.aapspharmsci.org/>.
30. McRobie CL, **Thompson GA**, Buch AB, Dato ME, Kelly SC, Agnew JR, Skuster JR, Mitchell DY. Bisoprolol Pharmacokinetics and Pharmacodynamics in Pediatric Subjects, 6 Months to 6 Years of Age. AAPS Pharmsci. 2(4), 2000. Available from: <http://www.aapspharmsci.org/>.

31. McRobie CL, **Thompson GA**, Dato ME, Johnson T, Seeck MJ, Russell DA, Skuster, JR, Mitchell DY: Pharmacokinetics of Ziac (bisoprolol fumarate/hydrochlorothiazide) and Zebeta (bisoprolol fumarate) in Children, 6 through 15 Years of Age. AAPS PharmSci. 2(4), 2000. Available from: <http://www.aapspharmsci.org/>.
32. Toothaker RD, Corey AE, Valentine SN, Agnew JR, Parekh N, **Thompson GA**, Powell JH: Pharmacokinetics and pharmacodynamics of coadministered azimilide dihydrochloride and digoxin. AAPS PharmSci. 3(3), 2001. Available from: <http://www.aapspharmsci.org/>.
33. Burgio D, Russell D, DeSilva B, Namour F, **Thompson G**: Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women. Clin Pharmacol Ther 71: P32, 2002
34. **Thompson GA**, Toothaker RD: The effect of nonlinear renal clearance on the assessment of relative bioavailability/systemic exposure using urinary excretion data. AAPS PharmSci 4(4): R6191, 2002. Available from: <http://www.aapspharmsci.org/>.
35. Bonate PL, Bhattaram VA, Bourne D, Brundage RC, Fabre D, Gibiansky L, Holford N, Huitema A, Hutcheson SJ, Hutmacher M, Jang IJ, Kaibara A, Klitgaard T, Kowalski K, Laveille C, Levasseur L, Liao S, Meibohm B, Mould D, Nichols AI, Nix DE, Nordle O, Peterson MC, Piotrovsky V, Robbie GJ, Sale M, Russell DA, **Thompson GA**, Thomson A, Wählby U, Williams G, Xiao A, Zhang X: Consistency of NONMEM Parameter Estimates Across Platforms and Compilers. AAPS PharmSci 4(4): R6240, 2002. Available from: <http://www.aapspharmsci.org/>.
36. El Mouelhi M, **Thompson GA**, Worley DJ, Kuzmak B, Destefano AJ: Influence of azimilide on CYP2C19 mediated metabolism. Clin Pharmacol Ther 73: P32, 2003.
37. Burgio DE, Lu Sun A, Russell DA, Whitham D, Eusebio R, **Thompson GA**: Comparison of daily (5 mg/day and 15 mg/day) oral dosing regimens of risedronate to healthy male and female volunteers. Clin Pharmacol Ther 73: P49, 2003.
38. El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, **Thompson GA**: Influence of ketoconazole on azimilide pharmacokinetics. AAPS Pharm Sci 5(S1), Abstract T3386, 2003. Available from: <http://www.aapspharmsci.org/>.
39. **Thompson GA**, Burgio DE, Bishop N, Russell DR, Sun LA: Risedronate Pharmacokinetics in Children with Osteogenesis Imperfecta. Bone 36(Supplement 1): S82, 2005; Bone 36 (Supplement 2): S223-S224, 2005.

40. **Thompson G**, El Mouelhi M, Worley D, Kuzmak B, DeStefano A: Effect of smoking and ethnicity on azimilide pharmacokinetics following single dose oral administration. The AAPS Journal 7 (Supplement 2): Abstract M1292, 2005. Available from: <http://www.aapsj.org/>
41. **Thompson GA**, Russell DA, Schnell DJ, Burgio DE, Sun LA: Risedronate Pharmacokinetics Following Daily and Monthly Dosing Regimens. Calcif Tissue Int 78: S162, 2006; J Bone Min Res 21 (Supplement 1): S291, 2006.
42. **Thompson GA**, Schnell DJ, Russell DA, Burgio DE, Sun LA: A Monthly Dosing Regimen of Risedronate Reduces Bone Turnover Similar to Daily Administration. Calcif Tissue Int 78: S161, 2006; J Bone Min Res 21 (Supplement 1): S111, 2006.
43. Johnson RD, Li L, Parish TH, **Thompson GA**: Population based assessment of the relationship between hemolytic activity and free pexelizumab serum concentrations. The AAPS Journal 8 (Supplement 2), Abstract T3376, 2006. Available from: <http://www.aapsj.org/>
44. Sica D, **Thompson GA**, El Mouelhi M, Janson WP, Wagner LK, DeStefano AJ: The Influence Of Azimilide On Creatinine Clearance. Clin Pharmacol Ther 81:S39, 2007.
45. Shumaker R, Aluri J, Fan J, Martinez G, **Thompson GA**, Ren M: Effect of ketoconazole coadministration on lenvatinib (E7080) exposure in healthy volunteers. Eur J Cancer 48: 37, 2012.
46. Dubbelman AC, Rosing H, Mergui-Roelvink M, Gupta A, Verbel D, Sellecchia R, Fan J, Thompson GA, Shumaker R, Huitema ADR, Beijnen JH, Schellens JHM: A mass balance study of ¹⁴C-lenvatinib (E7080) in patients with advance solid tumours or lymphomas. Br J Clin Pharmacol 76: 831-832, 2013.
47. Shumaker R, Aluri J, Fan J, Martinez G, **Thompson GA**, Ren M: Effects of rifampin (R) on the pharmacokinetics (PK) of lenvatinib (L) in healthy participants. Asia and Pacific Cancer 2013 Conference (APCC (encore presentation) and AACR-NCI-EORTC) (In press).

Presentations:

1. **Thompson GA**: "Pharmacokinetics", invited podium presentation, Lederle Program, Cincinnati, Ohio, September 16-17, 1981.
2. **Thompson GA**: "Bioavailability", invited podium presentation, Hamilton County Pharmaceutical Association, Cincinnati, Ohio, November 29, 1981.

3. **Thompson GA:** "Introduction to Pharmacokinetics", Continuing Education presentation, University of Cincinnati College of Pharmacy, April 19, 1983.
4. **Thompson GA:** "Overview on the Human Pharmacokinetics of Teicoplanin", invited podium presentation, Canadian Infectious Disease Society, Clinical Trials Committee, Toronto, Canada, March 6, 1985.
5. **Thompson GA,** Boxenbaum H, Keeley FJ, Theile JD, Okerholm RA: "Absorption and Disposition of Piroximone (MDL 19205) in Congestive Heart Failure", poster presentation, American Association of Pharmaceutical Scientist, Washington D.C., November 3, 1986.
6. **Thompson GA:** "Overview on the Disposition of Teicoplanin", podium presentation, National Committee on Clinical Laboratory Standards, Philadelphia, June 30, 1987.
7. **Thompson GA:** "General Aspects of Total Clearance", invited lecture, Ohio Northern University, College of Pharmacy, Ada, Ohio, April 4, 1988.
8. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA,** Kenny MT, Yuh L: "Pharmacokinetics of Teicoplanin in Intravenous Drug Abusers Being Treated for Endocarditis", podium presentation, Detroit Receiving Hospital and University Health Center, Department of Infectious Disease and Department of Pharmacy, Detroit, Michigan, September 16, 1988.
9. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA,** Kenny MT, Yuh L: "Pharmacokinetics of Teicoplanin in Intravenous Drug Abusers Being Treated for Endocarditis", podium presentation, Teicoplanin Endocarditis Workshop, Scottsdale, Arizona, December 14-16, 1988.
10. Shumaker RC*, Boxenbaum H, **Thompson GA:** "Determination of Absorption Rates using ABSPLOTS", invited lecture, University of Cincinnati, College of Pharmacy, Cincinnati, Ohio, January 27, 1989.
11. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA,** Kenny MT, Yuh L: "Pharmacokinetics of Teicoplanin in Intravenous Drug Abusers Being Treated for Endocarditis", podium presentation, University of Illinois Chicago, Department of Infectious Disease and Department of Pharmacy, Chicago, Illinois, June 1, 1989.
12. **Thompson GA:** "Basic Concepts of Drug Absorption, Distribution and Elimination", invited podium presentation, Alpha Zeta Omega Continuing Education Seminar, Cincinnati, Ohio, May 6, 1990.

13. Pedraz JL, Calvo B, Smithers JA, **Thompson GA**: "Pharmacokinetic-Pharmacodynamic Modeling: Time-dependent protein binding, an alternative interpretation of clockwise and counterclockwise hysteresis", podium presentation, American Association of Pharmaceutical Scientist, Las Vegas, Nevada, November 4-8, 1990.
14. Antony KK, Lewis EW, Kenny MT, Dulworth JK, Brackman MB, Kuzma R, Yuh L, Eller MG, **Thompson GA**: "Pharmacokinetics and Bioavailability of Teicoplanin Following Single Dose Intravenous and Intramuscular Administration of 6 mg/kg to Normal, Healthy, Male Volunteers", poster presentation, American Association of Pharmaceutical Scientist, Las Vegas, Nevada, November 4-8, 1990.
15. Smithers JA, **Thompson GA**, Kenny MT, Dulworth JK, Kulmala HK, Lewis EW, Ruberg SJ, Shapiro BE, Keane WF, Halstenson CE: "Applicability of Teicoplanin Dosage Adjustment Nomograms for Renally Impaired Patients Over the Range of 3 to 30 mg/kg", poster presentation, American Association of Pharmaceutical Scientist, Washington, D.C., November 17-21, 1991.
16. Smithers JA, Kulmala HK, **Thompson GA**, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA: "Pharmacokinetics of Teicoplanin Upon Multiple Dose Intravenous Administration of 3, 12 and 30 mg/kg to Normal Healthy Male Volunteers", poster presentation, American Association of Pharmaceutical Scientist, Washington, D.C., November 17-21, 1991.
17. Smithers JA, Kulmala HK, **Thompson GA**, Antony KK, Lewis EW, Ruberg SJ, Kenny MT, Dulworth JK, Brackman MA: "Pharmacokinetics of Teicoplanin Upon Multiple Dose Intravenous Administration of 3, 12 and 30 mg/kg to Normal Volunteers", podium presentation, Teicoplanin Endocarditis Workshop: Part II, Tucson, Arizona, March 19-22, 1992.
18. Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, **Thompson GA**, Kenny MT, Yuh L: "Pharmacokinetics of Teicoplanin in Intravenous Drug Abusers Being Treated for Endocarditis", podium presentation, University of Cincinnati, College of Pharmacy, February 19, 1992.
19. **Thompson GA**: "Role of Pharmacokinetics/Pharmacodynamics in Drug Development", podium presentation, University of Cincinnati, College of Pharmacy, March 2, 1992.
20. **Thompson GA**: "Role of "Population" Pharmacokinetics/Pharmacodynamics in Drug Development: Past, Present and Future", podium presentation, Midwest User Group for Population PK/PD Analysis, Indianapolis, April 14, 1993.
21. **Thompson GA**: "Population Pharmacokinetics: What Will They Think of Next?" Moderator, Round Table Discussion, Midwest User Group for Population PK/PD Analysis, Indianapolis, April 14, 1993.

22. **Thompson GA**, St. Peter JV, Heise MA, Horowitz ZD, Salyers GC, Charles TT, Brezovic C, Russell DA, Skare JA, Powell JH: "Influence Of Doxylamine Succinate On Mixed Function Oxidase Activity Upon Multiple Dose, Oral Administration", poster presentation, American Association of Pharmaceutical Scientist, San Diego, California, November 7-10, 1994.
23. **Thompson GA**, St. Peter JV, Heise MA, Horowitz ZD, Salyers GC, Charles TT, Brezovic C, Russell DA, Skare JA, Powell JH: "The Influence Of Doxylamine Succinate On Mixed Function Oxidase Activity and Thyroid Function Upon Multiple Dose, Peroral Administration", podium presentation, University of Cincinnati, College of Pharmacy, March 31, 1995.
24. **Thompson GA**, Barker SH, Brezovic CP, Williams MB, Powell JH, Kindberg CG: "Ibuprofen Pharmacokinetics are Stereoselectively Altered by Food", poster presentation, American Association of Pharmaceutical Scientist, Seattle, Washington, October 27 -31, 1996.
25. **Thompson GA**, Powell JH, Mallikaarjun S: "Bisphosphonate Renal Clearance: Assessment of Linearity", podium presentation, Midwest User Group for Population Approaches in Data Analysis 5th Annual Meeting, Ann Arbor, May 7, 1997.
26. **Thompson GA**, Powell JH, Mallikaarjun S: "Bisphosphonate renal clearance: Assessment of linearity ", poster presentation, American Association of Pharmaceutical Scientist, Boston, Massachusetts, November 2-6, 1997.
27. Corey AE, Agnew JR, Comer PF, Dilzer S, Lasseter K, Parekh N, Powell JH, Valentine S, **Thompson GA**: "Effect of Hepatic Impairment on Azimilide Pharmacokinetics Following Single Dose Oral Administration", poster presentation, American Association of Pharmaceutical Scientist, San Francisco, California, November 16-19, 1998.
28. **Thompson GA**: "Role of Pharmacokinetics/Pharmacodynamics in Drug Development", podium presentation, University of Cincinnati Graduate Student Seminar, College of Pharmacy, January 29, 1999.
29. Corey AE, Agnew JR, Valentine SN, Parekh, Powell JH, **Thompson GA**: "Effect of Severe Renal Impairment on Azimilide Pharmacokinetics Following Single Dose Oral Administration", poster presentation, American Association of Pharmaceutical Scientist, New Orleans, Louisiana, November 14-18, 1999.
30. Phillips L, **Thompson GA**, Grasella TH, Agnew JR: "Phase III Population Pharmacokinetics and Pharmacodynamics of Azimilide", poster presentation, American Association of Pharmaceutical Scientist, New Orleans, Louisiana, November 14-18, 1999.

31. **Thompson GA:** "Population Pharmacokinetics/Pharmacodynamics: Its Role in Clinical Drug Development", podium presentation, University of Cincinnati, College of Pharmacy Sesquicentennial Scientific Symposium, From Bench to Bedside: Innovations in Drug Development, February 17, 2001.
32. **Thompson GA, Toothaker RD:** "The Effect of Nonlinear Renal Clearance on the Assessment of Relative Bioavailability/Systemic Exposure using Urinary Excretion Data", poster presentation, American Association of Pharmaceutical Scientist, Toronto, Canada, November 10-14, 2002.
33. El Mouelhi M, **Thompson GA**, Worley DJ, Kuzmak B, Destefano AJ: "Influence of Azimilide on CYP2C19 Mediated Metabolism", poster presentation, American Society of Clinical Pharmacology and Therapeutics, Washington DC, April 2-5, 2003.
34. El Mouelhi M, Worley DJ, Kuzmak B, Destefano AJ, **Thompson GA:** "Influence of Ketoconazole on Azimilide Pharmacokinetics", poster presentation, American Association of Pharmaceutical Scientist, Salt Lake City, Utah, October 26-30, 2003.
35. **Thompson GA**, Burgio DE, Bishop N, Russell DR, Sun LA: "Risedronate Pharmacokinetics in Children with Osteogenesis Imperfecta", poster presentation, Third International Conference on Children's Bone Health, Sorrento, Italy, May 11-14, 2005.
36. **Thompson GA**, Burgio DE, Bishop N, Russell DR, Sun LA: "Risedronate Pharmacokinetics in Children with Osteogenesis Imperfecta", poster presentation, Second Joint Meeting of the European Calcified Tissue Society and the International Bone and Mineral Society, Geneva, Switzerland, June 25-29, 2005.
37. **Thompson G**, El Mouelhi M, Worley D, Kuzmak B, DeStefano A: "Effect of Smoking and Ethnicity on Azimilide Pharmacokinetics Following Single Dose Oral Administration", poster presentation, American Association of Pharmaceutical Scientist, Nashville, Tennessee, November 6-10, 2005.
38. **Thompson GA**, Russell DA, Schnell DJ, Burgio DE, Sun LA: "Risedronate Pharmacokinetics Following Daily and Monthly Dosing Regimens", poster presentation, European Symposium on Calcified Tissues, Prague, Czech Republic, May 10 – 14, 2006.
39. **Thompson GA**, Schnell DJ, Russell DA, Burgio DE, Sun LA: "A Monthly Dosing Regimen of Risedronate Reduces Bone Turnover Similar to Daily Administration", poster presentation, European Symposium on Calcified Tissues, Prague, Czech Republic, May 10 – 14, 2006.
40. **Thompson GA**, Schnell DJ, Russell DA, Burgio DE, Sun LA: "A Monthly Dosing Regimen of Risedronate Reduces Bone Turnover Similar to Daily Administration", poster presentation, American Society for Bone and Mineral Research, Philadelphia, September 15 – 19, 2006.

41. **Thompson GA**, Russell DA, Schnell DJ, Burgio DE, Sun LA: “Risedronate Pharmacokinetics Following Daily and Monthly Dosing Regimens”, plenary poster and poster presentations, American Society for Bone and Mineral Research, Philadelphia, September 15 – 19, 2006.
42. Johnson RD, Li L, Parish TH, **Thompson GA**: “Population based assessment of the relationship between hemolytic activity and free pexelizumab serum concentrations”, poster presentation, American Association of Pharmaceutical Scientist, San Antonio, Texas, October 29-November 2, 2006.
43. Sica D, **Thompson GA**, El Mouelhi M, Janson WP, Wagner LK, DeStefano AJ: “The Influence Of Azimilide On Creatinine Clearance”, poster presentation, American Society of Clinical Pharmacology and Therapeutics, Anaheim, California, March 21 – 24, 2007.
44. **Thompson GA**: "Concepts in Pharmacodynamics and Pharmacokinetic/ Pharmacodynamic Modeling: Theory", University of Cincinnati College of Pharmacy, 2009 - 2014.

Submitted Articles/Abstracts

Dubbelman AC, Rosing H, Nijenhuis C, Huitema ADR, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JHM, Beijnen JH: Pharmacokinetics and excretion of ¹⁴C-lenvatinib in patients with advance solid tumours or lymphomas. (Invest New Drugs; manuscript)

To Be Submitted

Johnson RD, Li L, Parish TH, Thompson GA: Population based assessment of the relationship between hemolytic activity and free pexelizumab serum concentrations.

Pathirana S, Jayawardena S, Thompson GA: Brompheniramine and Chlorpheniramine Pharmacokinetics Following Single-Dose Oral Administration in Children Ages 2 to 17 Years.

Shumaker RC, Ren M, Fan J, Chen H, Martinez G, Thompson GA, Pentikis HS: Influence of Renal Impairment on the Pharmacokinetics of Single-Dose Lenvatinib (J Clin Pharmacol)